MA71753A - Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble - Google Patents

Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble

Info

Publication number
MA71753A
MA71753A MA71753A MA71753A MA71753A MA 71753 A MA71753 A MA 71753A MA 71753 A MA71753 A MA 71753A MA 71753 A MA71753 A MA 71753A MA 71753 A MA71753 A MA 71753A
Authority
MA
Morocco
Prior art keywords
intermediates
preparation
guanylate cyclase
soluble guanylate
novel processes
Prior art date
Application number
MA71753A
Other languages
English (en)
Inventor
Ahmad Hashash
Song Xue
Takashi Nakai
Vishnu Vardhan Reddy Karnati
Wayne C. Schairer
Debra Jane Wallace
Fenger ZHOU
Yuguang Wang
William KISSEL
Original Assignee
Cyclerion Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2018/076982 external-priority patent/WO2019161534A1/fr
Application filed by Cyclerion Therapeutics, Inc. filed Critical Cyclerion Therapeutics, Inc.
Publication of MA71753A publication Critical patent/MA71753A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA71753A 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble MA71753A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862615678P 2018-01-10 2018-01-10
PCT/CN2018/076982 WO2019161534A1 (fr) 2018-02-22 2018-02-22 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble
EP25174051.0A EP4570797A3 (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble

Publications (1)

Publication Number Publication Date
MA71753A true MA71753A (fr) 2025-05-30

Family

ID=65279655

Family Applications (2)

Application Number Title Priority Date Filing Date
MA71753A MA71753A (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble
MA051565A MA51565A (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA051565A MA51565A (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble

Country Status (17)

Country Link
US (5) US11274096B2 (fr)
EP (3) EP4570797A3 (fr)
JP (2) JP7357621B2 (fr)
KR (3) KR20250002720A (fr)
CN (3) CN118184645A (fr)
AU (3) AU2019206560B2 (fr)
BR (1) BR112020013985A2 (fr)
CA (1) CA3087943A1 (fr)
CL (3) CL2020001814A1 (fr)
ES (1) ES2963447T3 (fr)
IL (3) IL314714A (fr)
JO (1) JOP20200165A1 (fr)
MA (2) MA71753A (fr)
MX (3) MX2020007364A (fr)
SG (1) SG11202006311SA (fr)
TW (2) TWI888947B (fr)
WO (1) WO2019140095A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563077B (zh) 2016-07-07 2026-03-10 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
US11274096B2 (en) 2018-01-10 2022-03-15 Cyclerion Therapeutics, Inc. Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
CN118221651A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
AU2023412228A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588465B1 (fr) * 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc
EA033168B1 (ru) * 2013-03-15 2019-09-30 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
EP3094327A1 (fr) * 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de la sgc pour le traitement de troubles neuromusculaires
EP3194382B1 (fr) 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Dérivés de pyrazole utilisés comme stimulateurs de sgc
EA201790627A1 (ru) * 2014-09-17 2017-09-29 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ рГЦ
CA3006746C (fr) 2015-11-30 2024-01-30 Ironwood Pharmaceuticals, Inc. Dispersions solides comprenant un stimulateur de guanylate cyclase soluble (sgc)
CN109563086B (zh) 2016-07-07 2023-05-23 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的方法
CN109563077B (zh) 2016-07-07 2026-03-10 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的新方法
US11274096B2 (en) 2018-01-10 2022-03-15 Cyclerion Therapeutics, Inc. Processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Also Published As

Publication number Publication date
EP3737679C0 (fr) 2023-09-06
US11274096B2 (en) 2022-03-15
SG11202006311SA (en) 2020-07-29
KR20200106920A (ko) 2020-09-15
AU2025202281A9 (en) 2025-05-15
AU2023270260B2 (en) 2026-01-29
AU2019206560B2 (en) 2023-08-24
US11708361B2 (en) 2023-07-25
MX2020007364A (es) 2020-11-18
US20220024909A1 (en) 2022-01-27
US12030874B2 (en) 2024-07-09
WO2019140095A8 (fr) 2020-06-18
JP2021511299A (ja) 2021-05-06
IL319883A (en) 2025-05-01
CL2022000907A1 (es) 2022-10-21
JOP20200165A1 (ar) 2022-10-30
ES2963447T3 (es) 2024-03-27
IL314714A (en) 2024-10-01
EP4570797A2 (fr) 2025-06-18
IL275748B1 (en) 2024-09-01
KR20250002720A (ko) 2025-01-07
EP4570797A3 (fr) 2025-09-03
IL275748A (en) 2020-08-31
KR20250048609A (ko) 2025-04-09
TW201932450A (zh) 2019-08-16
US20210053962A1 (en) 2021-02-25
IL275748B2 (en) 2025-01-01
JP2023182647A (ja) 2023-12-26
AU2025202281A1 (en) 2025-04-17
CA3087943A1 (fr) 2019-07-18
MA51565A (fr) 2020-11-18
TW202402741A (zh) 2024-01-16
KR102739727B1 (ko) 2024-12-05
CN111902410B (zh) 2024-04-19
US20240391911A1 (en) 2024-11-28
AU2023270260A1 (en) 2023-12-07
US20230339928A1 (en) 2023-10-26
TWI821237B (zh) 2023-11-11
CN111902410A (zh) 2020-11-06
EP4249469A2 (fr) 2023-09-27
EP3737679B1 (fr) 2023-09-06
MX2023000045A (es) 2023-02-01
JP7357621B2 (ja) 2023-10-06
JP7744955B2 (ja) 2025-09-26
CL2020001814A1 (es) 2020-11-06
EP4249469A3 (fr) 2023-12-27
TWI888947B (zh) 2025-07-01
CN118221665A (zh) 2024-06-21
WO2019140095A1 (fr) 2019-07-18
AU2019206560A1 (en) 2020-07-30
US12275724B2 (en) 2025-04-15
EP3737679A1 (fr) 2020-11-18
US20250361228A1 (en) 2025-11-27
BR112020013985A2 (pt) 2020-12-01
CN118184645A (zh) 2024-06-14
CL2022000904A1 (es) 2022-10-21
MX2023000044A (es) 2023-02-01

Similar Documents

Publication Publication Date Title
EP3504196A4 (fr) Procédés de préparation d'olaparib
EP3402787A4 (fr) Procédés de préparation d'acide 2,5-furandicarboxylique et des intermédiaires et dérivés correspondants
MA55082A (fr) Compositions, procédés, et kits pour l'administration de polyribonucléotides
EP3749769A4 (fr) Procédés de production d'alcaloïdes de type morphinane et de dérivés
EP3893655A4 (fr) Procédés pour la préparation d'un composition de protéines végétales
MA46479A (fr) Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène
MA46240A (fr) Compositions d'arn de haute pureté et procédés pour leur préparation
EP3315512A4 (fr) Procédé pour la préparation sélective d'un conjugué anticorps-médicament
MA71753A (fr) Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble
EP3635022A4 (fr) Procédés de préparation de monomères fluorés fonctionnalisés, monomères fluorés et compositions pour les préparer
MA53445A (fr) Procédés et compositions pour la modification de plantes
EP3294865A4 (fr) Procédés de production d'épimérases et d'alcaloïdes benzylisoquinoléine
EP3529232A4 (fr) Dérivés d'acide sulfamique et procédés pour leur préparation
EP3645049A4 (fr) Anticorps multispécifiques et procédés de préparation et d'utilisation associés
EP3675847A4 (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3488018A4 (fr) Procédés et compositions pour l'identification de protéines
EP3897717A4 (fr) Procédés de production d'anticorps hétérodimères
MA53391A (fr) Compositions pour l'agriculture et procédés associés
EP3720456A4 (fr) Procédés d'enrichissement améliorés pour la préparation de compositions d'acide tannique
EP3466280A4 (fr) Procédé de préparation d'aliments transformés et aliments transformés préparés au moyen de ce procédé
MA51307A (fr) Compositions laitières fermentées et procédés de préparation de celles-ci
EP3803416A4 (fr) Compositions et procédés de détection d'une lésion cérébrale traumatique
EP3889572A4 (fr) Procédé de préparation d'échantillon
IL263994B (en) Novel processes for preparation of soluble guanylate cyclase stimulators
EP3314001A4 (fr) Procédés et compositions pour la préparation d'éphédrine et de composés alcaloïdes apparentés